Literature DB >> 27842538

The modified Gingyo-san, a Chinese herbal medicine, has direct antibacterial effects against respiratory pathogens.

Tetsuya Yamada1, Takeaki Wajima2, Hidemasa Nakaminami2, Kaho Kobayashi2, Hideaki Ikoshi1, Norihisa Noguchi3.   

Abstract

BACKGROUND: Modified Gingyo-san (MGS) is empirically used to treat various respiratory infections. MGS has been reported to have antiinflammatory and antiviral activities; however, it is not known if it has an antibacterial activity. Therefore, in this study, we aimed to investigate the antimicrobial activity of MGS against respiratory pathogens.
METHODS: MGS, which is sold as an over-the-counter drug in Japan, was used for the study. Antimicrobial activity was evaluated using the disk diffusion method. Growth inhibitory activity was evaluated by measuring colony-forming units of the pathogens in the presence of MGS.
RESULTS: MGS inhibited the growth of Bacillus subtilis, Streptococcus pneumoniae, and Streptococcus pyogenes, which are gram-positive bacteria. Although the growth of most gram-negative bacteria was not inhibited by MGS, interestingly, the growth of Haemophilus influenzae was inhibited. MGS did not show any activity against Candida albicans or bacteriophage φX174.
CONCLUSIONS: In addition to the antiinflammatory and antiviral activities of MGS, which have already been reported, the data obtained from this study indicates that MGS has an antibacterial activity.

Entities:  

Keywords:  Chinese herbal medicine; Modified Gingyo-san; Respiratory pathogen

Mesh:

Substances:

Year:  2016        PMID: 27842538      PMCID: PMC5109643          DOI: 10.1186/s12906-016-1431-3

Source DB:  PubMed          Journal:  BMC Complement Altern Med        ISSN: 1472-6882            Impact factor:   3.659


Background

Respiratory infections are mainly caused by viruses or bacteria. Particularly, Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes are the major causative bacteria of respiratory infections. In several cases of respiratory infections, the aforementioned bacteria cause severe invasive infections [1-3]. Furthermore, these bacteria are developing resistance to the currently used antimicrobial agents, which can result in various clinical concerns [4]. This indicates the urgent need for developing novel antimicrobial agents. Until recently, the use of traditional medicines was focused mainly in alternative medicine. In traditional Chinese medicine, herbal medicines are used for the treatment of various respiratory infections. However, the use of such medicines is based on experience and is not supported by basic scientific evidence. These medicines have, however, been applied in many clinical settings. In recent years, many researchers have made efforts to establish basic scientific evidences for the use of several herbal medicines used in traditional Chinese medicine because of evidence-based treatment. For example, it has been reported that Sho-sei-ryu-to and Ma-o-to have antiviral activities against the influenza virus [5-7]. Gingyo-san (GS) has also been reported to have antiviral activity against influenza virus and an immunomodulating activity [8-11]. Modified Gingyo-san (MGS) and GS are sold as over-the-counter (OTC) drugs. MGS is used to treat sore throats, coughs, and headaches. GS and MGS are composed of the crude drugs shown in Table 1. The individual components of MGS have been studied by several researchers. The roots of glycyrrhiza and platycodon, which are included in MGS, have been reported to have antiinflammatory and antitussive activities [12, 13]. In addition, schizonepeta spike and forsythia fruit have antibacterial activities against Propionibacterium acnes and thus, they are used for treating acne [14-16].
Table 1

Formulations of modified Gingyo-san and Gingyo-san

ContentModified Gingyo-san (MGS)aAmount (g)b Gingyo-san (GS) Amount (g)b
Lonicerae Flos4.2630.0
Forsythiae Fructus4.2630.0
Glycyrrhizae Radix2.5615.0
Platycodi Radix2.5618.0
Menthae Herba2.5618.0
Arctii Fructus2.1418.0
Schizonepetae Spica1.712.0
Fermented soybean2.1412.0
Lophatherum Herba1.715.0
Antelope Horns0.13-

aextract

bdaily dose

Formulations of modified Gingyo-san and Gingyo-san aextract bdaily dose Therefore, MGS has a potential use in the treatment of various symptoms of infectious diseases. In this study, we evaluated the direct effects of MGS on pathogenic bacteria to establish a basic evidence of its antibacterial activity.

Methods

Microbial strains and culture conditions

The microbial strains used in this study are listed in Table 2. All the microbes, except the streptococci and H. influenzae, were cultured using Mueller-Hinton broth or agar (Oxoid Ltd., Hampshire, UK). The streptococci and H. influenzae were cultured using blood agar or Todd-Hewitt broth (Oxoid Ltd.) and chocolate agar or brain heart infusion broth (Oxoid Ltd.) supplemented with 15 μg/mL of nicotinamide adenine dinucleotide solution and 15 μg/mL of hemin solution, respectively.
Table 2

Bacterial, fungal and viral strains used in this study

MicroorganismDescription
Gram-positive bacteria
Staphylococcus aureus JCM2874Quality control strain for susceptibility test, Methicillin-susceptible
Staphylococcus aureus N315Methicillin-resistant S. aureus
Streptococcus pneumoniae ATCC49619Quality control strain for susceptibility test, penicillin-susceptible
Streptococcus pneumoniae 19FClinical isolate, penicillin-resistant S. pneumoniae, serotype 19F
Streptococcus pyogenes JCM5674Type strain
Enterococcus faecalis ATCC29212Quality control strain for susceptibility test
Bacillus subtilis ATCC6633Control strain for various assays
Gram-negative bacteria
Escherichia coli ATCC25922Quality control strain for susceptibility test
Escherichia coli CHost of bacteriophage φX174
Pseudomonas aeruginosa ATCC27853Quality control strain for susceptibility test
Haemophilus influenzae ATCC49247Quality control strain for susceptibility test
Serratia marcescens ATCC13880Type strain
Fungi
Candida albicans ATCC10231Quality control strain for various assays
Bacteriophage
 φX174Virulent phage for E. coli C
Bacterial, fungal and viral strains used in this study

Disk diffusion method

MGS was obtained from ISKRA Industry (Tokyo, Japan). The disk diffusion antimicrobial test was conducted as follows. Briefly, 8-mm paper disks were impregnated with MGS suspension to obtain 8 mg of MGS/disk. The bacteria were suspended in 0.75% agar containing Mueller-Hinton broth and poured into suitable petri dishes. The disks were placed on the set agar and the plates were incubated at 35 °C overnight, after which the zones of growth inhibition were measured.

Evaluation of growth inhibitory activity

A single colony of bacteria was inoculated into the appropriate broth medium and incubated at 37 °C overnight. The culture was diluted with the broth (1:100), with or without MGS, and incubated at 37 °C with shaking. A 100-μL of the culture was sampled at 0, 1, 2, 4, and 6 h after incubation and diluted with phosphate-buffered saline (PBS). Serial dilutions were then plated on the appropriate agar plates and incubated at 37 °C overnight. Afterwards, the numbers of grown colonies were counted. All the experiments were performed at least twice on independent days. It was also confirmed that all the experiments showed similar results.

Plaque assay

MGS was mixed with bacteriophage φX174. The mixtures were diluted with PBS and further mixed with Escherichia coli C and 0.75% agar. The mixtures were then poured onto nutrient agar and incubated at 37 °C for 12 h, after which the plaques were counted.

Cell proliferation assay

Cell proliferation activities with or without MGS were performed using CellTiter 96 Aqueous One Solution Cell Proliferation Assay Kit (Promega, Madison, MI, USA). Monolayer human lung epithelial cell lines (A549 cells) were grown using Eagle’s minimal essential medium, to which 10% fetal calf serum had been added, in 96-well plates. Aliquots of MGS were then added and the plates were incubated at 37 °C for 3 h under 5% CO2. After incubation, the numbers of living cells were determined using the kit according to the manufacturer’s instructions [17].

Statistical analysis

We assessed statistical significance of differences for growth in the presence or absence of MGS. We performed Student’s and Welch’s t-tests using JMP software (SAS Institute Inc., NC, USA). P < 0.05 were judged as significant difference.

Results and discussion

Antimicrobial activity of MGS

The disk diffusion method is used as a screening test for the antimicrobial activities of drugs and natural products [18, 19]. The susceptibility disk method was therefore used to determine whether MGS has antimicrobial activity (Table 3). Zones of growth inhibition were obtained in the experiments involving S. pneumoniae and S. pyogenes but not in those involving the other pathogens. This data indicates that MGS has a direct antibacterial activity against S. pneumoniae and S. pyogenes.
Table 3

Inhibitory zone of modified Gingyo-san containing paper diska

StrainInhibitory zone (mm)b
Staphylococcus aureus JCM2874-
Staphylococcus aureus N315-
Streptococcus pneumoniae ATCC4961910.0
Streptococcus pneumoniae 19F10.0
Streptococcus pyogenes JCM56748.5
Enterococcus faecalis ATCC29212-
Bacillus subtilis ATCC6633-
Escherichia coli ATCC25922-
Pseudomonas aeruginosa ATCC27853-
Haemophilus influenzae ATCC49247-

a8 mg/disk

b- , inhibitory zone not appeared

Inhibitory zone of modified Gingyo-san containing paper diska a8 mg/disk b- , inhibitory zone not appeared

Growth inhibitory activity of MGS against respiratory pathogens

The susceptibility disk test is suitable for screening the antimicrobial activities of drugs; however, not all drugs that have antimicrobial activities produce zones of growth inhibition, which may be due to the chemical properties of the drugs [20]. Therefore, to validate the growth inhibitory effect of MGS, bacterial colony-forming units (CFUs) in cultures were monitored over time in the presence or absence of MGS. The number of CFUs of B. subtilis ATCC6633, which is normally used for testing the antibacterial activity of drugs, decreased in a dose-dependent manner after the addition of MGS to the culture medium (Fig. 1). MGS is usually administered with approximately 100 mL of water; thus, after administration, the concentration of MGS in the oral cavity reaches approximately 24 mg/mL. Since MGS was used at a concentration equivalent to its usually administered dose, the data obtained indicates that MGS has a direct antibacterial effect at its normal dose.
Fig. 1

Antibacterial effect of modified Gingyo-san against Bacillus subtilis ATCC6633. This experiment was performed twice on independent occasions and similar results were obtained. The data shown is representative of the results obtained

Antibacterial effect of modified Gingyo-san against Bacillus subtilis ATCC6633. This experiment was performed twice on independent occasions and similar results were obtained. The data shown is representative of the results obtained The antimicrobial activity of MGS was analyzed at a concentration was 20 mg/mL. The growth of S. aureus, S. pneumoniae, S. pyogenes, and Enterococcus faecalis was significantly inhibited by the addition of MGS to the respective culture media (Fig. 2). MGS also inhibited the growth of antimicrobial-resistant strains such as methicillin-resistant S. aureus (MRSA) and penicillin-resistant S. pneumoniae (PRSP) (Fig. 2). Therefore, these results indicate that MGS has growth inhibitory effects against gram-positive bacteria. However, the growth of E. coli and Pseudomonas aeruginosa was not inhibited (Fig. 2). In addition, MGS did not affect other gram-negative bacteria such as Acinetobacter baumannii, Serratia marcescens, and Klebsiella pneumoniae (data not shown).
Fig. 2

Antibacterial effects of modified Gingyo-san against several bacterial strains. a S. aureus JCM2874; b S. aureus N315 (MRSA); c S. pneumoniae ATCC49619; d S. pneumoniae 19F; e S. pyogenes JCM5674; f E. faecalis ATCC29212; g E. coli ATCC25922; h P. aeruginosa ATCC27853; and i H. influenzae ATCC49247. Each experiment was performed three times on independent occasions and similar results were obtained. The P value was calculated by Welch’s t-test. ** P < 0.01, *P < 0.05

Antibacterial effects of modified Gingyo-san against several bacterial strains. a S. aureus JCM2874; b S. aureus N315 (MRSA); c S. pneumoniae ATCC49619; d S. pneumoniae 19F; e S. pyogenes JCM5674; f E. faecalis ATCC29212; g E. coli ATCC25922; h P. aeruginosa ATCC27853; and i H. influenzae ATCC49247. Each experiment was performed three times on independent occasions and similar results were obtained. The P value was calculated by Welch’s t-test. ** P < 0.01, *P < 0.05 However, interestingly, the growth of H. influenzae, which is a major causative pathogen of respiratory infections, was significantly inhibited in spite of it being a gram-negative bacterium (Fig. 2). It has been reported that among gram-negative bacteria, H. influenzae has a different cell surface structure [21]. In addition, the chromosomal efflux pumps of H. influenzae are fewer than those of other gram-negative bacteria [22]. The aforementioned factors might therefore be related to the observed bactericidal effect of MGS on H. influenzae in this study. These findings indicate that MGS can comprehensively inhibit the growth of respiratory bacterial pathogens. Moreover, MGS showed inhibitory effects against MRSA and PRSP, which suggests that MGS could be a very useful antibiotic for the treatment of respiratory infections.

Effects of MGS on Candida albicans and bacteriophage φX174

The inhibitory effects of MGS on eukaryotes and viruses were analyzed using Candida albicans and bacteriophage φX174 as the eukaryotic and viral models, respectively (Fig. 3). The data obtained indicated that MGS does not inhibit the growth of C. albicans or bacteriophage φX174. In addition, MGS did not show any antiproliferative effects against the A549 cells (Fig. 4). These findings indicate that MGS might not have any direct effect on eukaryotes or viruses.
Fig. 3

Antifungal and antibacteriophage effects of modified Gingyo-san. a C. albicans ATCC10231 and b bacteriophage φX174. Each experiment was performed 3 times on independent occasions and similar results were obtained

Fig. 4

Effect of modified Gingyo-san on a eukaryotic cell. Proliferation activity was evaluated. Each experiment was performed 3 times on independent occasions. The P value was calculated by student’s t-test

Antifungal and antibacteriophage effects of modified Gingyo-san. a C. albicans ATCC10231 and b bacteriophage φX174. Each experiment was performed 3 times on independent occasions and similar results were obtained Effect of modified Gingyo-san on a eukaryotic cell. Proliferation activity was evaluated. Each experiment was performed 3 times on independent occasions. The P value was calculated by student’s t-test

Conclusions

Our study indicated that MGS has a direct antibacterial effect against respiratory bacterial pathogens. These findings together with those from previous reports show that, GS has in vivo antiviral activity against the influenza virus and that MGS could be a useful antibacterial agent. Therefore, MGS may be effective for use as a pastille and a gargle. Moreover, future studies need be conducted to clarify whether the metabolites of MGS as well have effects on bacteria.
  20 in total

1.  Structural models for the cell surface lipooligosaccharides of Neisseria gonorrhoeae and Haemophilus influenzae.

Authors:  N J Phillips; C M John; L G Reinders; B W Gibson; M A Apicella; J M Griffiss
Journal:  Biomed Environ Mass Spectrom       Date:  1990-11

2.  Protective and immunomodulatory effect of Gingyo-san in a murine model of acute lung inflammation.

Authors:  Chia-Chou Yeh; Chih-Che Lin; Shulhn-Der Wang; Che-Ming Hung; Ming-Hsien Yeh; Ching-Ju Liu; Shung-Te Kao
Journal:  J Ethnopharmacol       Date:  2006-12-20       Impact factor: 4.360

3.  Xiao-Qing-Long-Tang (Sho-seiryu-to) inhibited cytopathic effect of human respiratory syncytial virus in cell lines of human respiratory tract.

Authors:  Jung San Chang; Chia Feng Yeh; Kuo Chih Wang; Den En Shieh; Ming Hong Yen; Lien Chai Chiang
Journal:  J Ethnopharmacol       Date:  2013-03-27       Impact factor: 4.360

4.  Molecular epidemiologic characteristics of Streptococcus pneumoniae isolates from children with meningitis in Japan from 2007 through 2009.

Authors:  Fuminori Sakai; Naoko Chiba; Akiko Ono; Somay Yamagata Murayama; Kimiko Ubukata; Keisuke Sunakawa; Takashi Takahashi
Journal:  J Infect Chemother       Date:  2010-12-15       Impact factor: 2.211

5.  Distribution of emm type and antibiotic susceptibility of group A streptococci causing invasive and noninvasive disease.

Authors:  Takeaki Wajima; Somay Y Murayama; Katsuhiko Sunaoshi; Eiichi Nakayama; Keisuke Sunakawa; Kimiko Ubukata
Journal:  J Med Microbiol       Date:  2008-11       Impact factor: 2.472

6.  Mechanism of anti-inflammatory action of glycyrrhizin: effect on neutrophil functions including reactive oxygen species generation.

Authors:  H Akamatsu; J Komura; Y Asada; Y Niwa
Journal:  Planta Med       Date:  1991-04       Impact factor: 3.352

7.  Antibiotic susceptibility in relation to genotype of Streptococcus pneumoniae, Haemophilus influenzae, and Mycoplasma pneumoniae responsible for community-acquired pneumonia in children.

Authors:  Miyuki Morozumi; Naoko Chiba; Takafumi Okada; Hiroshi Sakata; Keita Matsubara; Satoshi Iwata; Kimiko Ubukata
Journal:  J Infect Chemother       Date:  2012-10-30       Impact factor: 2.211

8.  In vivo anti-influenza virus activity of Kampo (Japanese herbal) medicine "sho-seiryu-to"--stimulation of mucosal immune system and effect on allergic pulmonary inflammation model mice.

Authors:  T Nagai; H Yamada
Journal:  Immunopharmacol Immunotoxicol       Date:  1998-05       Impact factor: 2.730

9.  Propionibacterium acnes biotypes and susceptibility to minocycline and Keigai-rengyo-to.

Authors:  Shuichi Higaki; Motokazu Nakamura; Masaaki Morohashi; Takayoshi Yamagishi
Journal:  Int J Dermatol       Date:  2004-02       Impact factor: 2.736

10.  Gingyo-san enhances immunity and potentiates infectious bursal disease vaccination.

Authors:  Che-Ming Hung; Chia-Chou Yeh; Kowit-Yu Chong; Hsiao-Ling Chen; Jiun-Yu Chen; Shung-Te Kao; Chih-Ching Yen; Ming-Hsien Yeh; Maw-Sun Lin; Chuan-Mu Chen
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-25       Impact factor: 2.629

View more
  5 in total

1.  Herbal Medicine (Sihogayonggolmoryeo-Tang or Chai-Hu-Jia-Long-Gu-Mu-Li-Tang) for Treating Hypertension:A Systematic Review and Meta-Analysis.

Authors:  Boram Lee; Chan-Young Kwon
Journal:  Evid Based Complement Alternat Med       Date:  2020-09-09       Impact factor: 2.629

2.  Tokiinshi, a traditional Japanese medicine (Kampo), suppresses Panton-Valentine leukocidin production in the methicillin-resistant Staphylococcus aureus USA300 clone.

Authors:  Yuka Maezawa; Hidemasa Nakaminami; Shunsuke Takadama; Minami Hayashi; Takeaki Wajima; Keisuke Nakase; Tetsuya Yamada; Hideaki Ikoshi; Norihisa Noguchi
Journal:  PLoS One       Date:  2019-03-28       Impact factor: 3.240

3.  Efficacy and safety of Sihogayonggolmoryeo-tang (Saikokaryukotsuboreito, Chai-Hu-Jia-Long-Gu-Mu-Li-Tang) for post-stroke depression: A systematic review and meta-analysis.

Authors:  Chan-Young Kwon; Boram Lee; Sun-Yong Chung; Jong Woo Kim; Aesook Shin; Ye-Yong Choi; Younghee Yun; Jungtae Leem
Journal:  Sci Rep       Date:  2019-10-10       Impact factor: 4.379

4.  Effectiveness and safety of Hwangryunhaedok-Tang (Huang-Lian-Jie-Du-Tang, Oren-Gedoku-to) for dyslipidemia: A protocol for a PRISMA-compliant systematic review and meta-analysis.

Authors:  Boram Lee; Chan-Young Kwon
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

5.  In vitro growth-inhibitory effects of Portulaca oleracea L. formulation on intestinal pathogens.

Authors:  Sae Okuda; Takeaki Wajima; Tetsuya Yamada; Hidemasa Nakaminami; Hideaki Ikoshi; Norihisa Noguchi
Journal:  Access Microbiol       Date:  2021-02-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.